Tango Therapeutics and Revolution Medicines reported additional early-stage evidence for a pancreatic cancer combination built around vopimetostat, a PRMT5 inhibitor, paired with Revolution’s RAS(ON) inhibitors. The combination follows an emerging signal of additive or synergistic activity in MTAP-deleted and RAS-mutant metastatic PDAC, supporting plans to advance clinical development toward later-stage studies.